PreVu(R) Skin Cholesterol Clinics Rollout Nationally
PreVu(R) Skin Cholesterol Clinics Rollout Nationally
Over 80 Pharmacies Preparing for Expanded Consumer Testing Across Canada
WINNIPEG, MANITOBA -- (Marketwire) -- 02/27/13 -- Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to provide the market with an update on a series of rolling PreVu(R) POC Skin Cholesterol Testing Clinics that are scheduled to be held across Canada throughout March and April and into the spring.
"Over 80 pharmacies under the London Drugs banner in Western Canada and the PharmaChoice banner in Eastern Canada, are currently preparing to launch PreVu POC Testing Clinics, in every province except Quebec, this coming March and April," said Paul Moreau, Vice President, Sales and Marketing for Miraculins Inc. "The London Drugs Clinics represent the second stage of PreVu POC Testing expansion plans through the pharmacy's chain and the PharmaChoice Clinics represent the leading edge of network expansion into PharmaChoice pharmacies in Eastern Canada. Expansion news related to the Quebec pharmacy segment is anticipated at the conclusion of sales and marketing discussions with interested parties currently underway."
"The commencement of these extensive PreVu POC Testing Clinics will also mark the continuation of an expansive public relations campaign by Miraculins to further raise marketplace awareness about the test and its benefits. In addition, specially developed educational programming is being made available to help educate healthcare professionals, general practitioners and lipid specialists about the science behind PreVu and the technology's clinical utility and application," added Moreau.
A complete list of the London Drugs and PharmaChoice PreVu POC Testing locations featuring clinics in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland for this March and April can be accessed at http://www.prevu.com/PreVu_Clinics.pdf. Additional locations will continue to be added in both Eastern and Western Canada in the months that follow, with the expectation that participating stores will transition to offering PreVu POC testing as an ongoing risk assessment service available either through walk-up request or by appointment, as well as through ongoing rotating clinics.
About the PreVu Non-Invasive Skin Cholesterol Test
The PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test is a non-invasive, risk assessment technology designed to measure skin cholesterol - an important new biomarker in assessing risk of coronary artery disease ("CAD"). The PreVu(R) POC Test is completely painless, non-invasive, involves no blood draw or needles, and requires no overnight fasting. This in vitro diagnostic test is conducted on the palm of the hand in less than 5 minutes with results being immediately available, facilitating point of care consultation and a next steps discussion. Skin cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and the skin contains approximately 11% of all the cholesterol found in the human body, by weight. Elevated skin cholesterol has been shown in clinical studies to be strongly associated with significant CAD as measured by treadmill stress testing and coronary angiography, as well as measured by testing for coronary calcium, carotid artery thickening, and carotid artery plaque. The PreVu POC Test does not diagnose the presence or absence of CAD, but helps to identify patients who may be at higher, hidden risk for CAD by measuring this new biomarker. For more information, visit www.prevu.com.
About Miraculins Inc.
Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu(R) technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company's preeclampsia program is partnered with Alere Inc., one of the world's largest diagnostic companies. For more information, visit www.miraculins.com.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.
PreVu(R) is a registered trademark of Miraculins Inc. All Rights Reserved. 2013.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Miraculins Inc. Paul J. Moreau Vice President, Sales & Marketing 204-478-5603 204-453-1546 (FAX)
Miraculins Inc. Christopher J. Moreau President & CEO 204-477-7599 204-453-1596 (FAX) email@example.com www.miraculins.com